Association of Common Variants in MMPs with Periodontitis Risk
Table 3
Meta-analysis results of the polymorphisms in MMPs gene on periodontitis risk.
MMP-1
−1607 1G/2G
Studies (cases/controls)
2G versus 1G OR (95% CI) (%), ,
2G/2G versus 1G/1G OR (95% CI) (%), ,
1G/2G versus 1G/1G OR (95% CI) (%), ,
2G/2G versus 1G/2G OR (95% CI) (%), ,
1G/2G + 2G/2G versus 1G/1G OR (95% CI) (%), ,
2G/2G versus 1G/1G + 1G/2G OR (95% CI) (%), ,
1G/2G versus 1G/1G + 2G/2G OR (95% CI) (%), ,
Type of disease
CP
Caucasian
3 (309/287)
1.02 (0.67–1.56)
1.05 (0.44–2.51)
0.95 (0.64–1.42)
0.90 (0.59–1.37)
0.91 (0.62–1.32)
0.89 (0.60–1.33)
1.00 (0.72–1.40)
63.1, 0.067, 1.000
63.0, 0.067, 1.000
12.0, 0.321, 1.000
0.0, 0.490, 1.000
49.9, 0.136, 1.000
38.2, 0.198, 1.000
0.0, 0.969, 1.000
Asian
2 (302/192)
1.75 (0.77–3.95)
2.79 (0.56–13.98)
1.31 (0.74–2.32)
1.75 (0.77–3.94)
1.96 (0.63–6.09)
2.01 (0.72–5.61)
0.79 (0.55–1.16)
84.5, 0.011, 1.000
81.5, 0.020, 1.000
27.0, 0.242, 1.000
64.6, 0.093, 1.000
69.4, 0.071, 1.000
79.7, 0.027, 1.000
0.0, 0.467, 1.000
AgP
Asian
2 (77/194)
1.34 (0.48–3.73)
1.54 (0.28–8.55)
0.91 (0.42–1.96)
1.67 (0.38–7.31)
1.14 (0.56–2.32)
1.64 (0.35–7.70)
0.75 (0.43–1.30)
84.8, 0.010, 1.000
78.4, 0.031, 1.000
0.0, 0.763, 1.000
81.8, 0.019, 1.000
39.0, 0.200, 1.000
85.7, 0.008, 1.000
59.5, 0.116, 1.000
Severe CP
Caucasian
Mild to moderate
2 (66/91)
0.99 (0.63–1.55)
0.99 (0.39–2.50)
1.16 (0.52–2.60)
0.85 (0.39–1.84)
1.10 (0.51–2.38)
0.89 (0.43–1.85)
1.17 (0.62–2.21)
0.0, 0.613, 1.000
0.0, 0.613, 1.000
0.0, 0.667, 1.000
0.0, 0.874, 1.000
0.0, 0.613, 1.000
0.0, 0.751, 1.000
0.0, 0.876, 1.000
Severe
2 (110/91)
1.53 (0.72–3.24)
2.44 (0.47–12.59)
1.52 (0.70–3.30)
1.31 (0.68–2.51)
1.68 (0.81–3.50)
1.47 (0.80–2.73)
0.98 (0.56–1.73)
65.7, 0.088, 1.000
63.4, 0.098, 1.000
15.8, 0.276, 1.000
0.0, 0.369, 1.000
51.1, 0.153, 1.000
42.3, 0.188, 1.000
0.0, 0.845, 1.000
Asian
Mild to moderate
2 (168/192)
1.26 (0.93–1.72)
1.62 (0.84–3.12)
1.40 (0.72–2.69)
1.19 (0.75–1.87)
1.51 (0.82–2.80)
1.27 (0.83–1.95)
0.97 (0.63–1.48)
60.1, 0.113, 0.987
62.7, 0.101, 1.000
43.8, 0.182, 1.000
0.0, 0.534, 1.000
56.0, 0.132, 1.000
21.0, 0.261, 1.000
0.0, 0.784, 1.000
Severe
2 (97/192)
1.99 (0.92–4.26)
2.93 (0.71–12.03)
1.16 (0.53–2.56)
2.19 (1.26–3.79)
1.78 (0.86–3.67)
2.55 (0.95–6.85)
0.58 (0.35–0.98)
73.5, 0.052, 0.546
67.0, 0.082, 0.952
0.0, 0.468, 1.000
48.9, 0.162, 0.035
38.1, 0.204, 0.854
69.7, 0.069, 0.441
0.0, 0.517, 0.287
Smoking habit in CP
Caucasian
Nonsmoking
3 (200/213)
0.92 (0.55–1.55)
0.90 (0.33–2.43)
0.87 (0.54–1.40)
0.85 (0.52–1.41)
0.96 (0.45–2.05)
0.82 (0.52–1.30)
0.98 (0.66–1.46)
66.1, 0.053, 1.000
63.1, 0.067, 1.000
34.9, 0.215, 1.000
0.0, 0.438, 1.000
56.9, 0.098, 1.000
40.1, 0.118, 1.000
0.0, 0.575, 1.000
Smoking
2 (109/74)
1.10 (0.71–1.72)
1.14 (0.43–3.02)
1.12 (0.54–2.34)
1.15 (0.50–2.64)
1.12 (0.55–2.29)
1.19 (0.53–2.65)
0.98 (0.53–1.84)
19.0, 0.267, 1.000
32.9, 0.222, 1.000
0.0, 0.976, 1.000
52.2, 0.148, 1.000
0.0, 0.682, 1.000
54.0, 0.140, 1.000
0.0, 0.319, 1.000
MMP-1
−519 A/G
Studies (cases/controls)
G versus A OR (95% CI) (%), ,
GG versus AA OR (95% CI) (%), ,
AG versus AA OR (95% CI) (%), ,
GG versus AG OR (95% CI) (%), ,
AG + GG versus AA OR (95% CI) (%), ,
GG versus AA + AG OR (95% CI) (%), ,
AG versus AA + GG OR (95% CI) (%), ,
Type of disease
CP
Caucasian
2 (235/293)
1.03 (0.80–1.32)
1.08 (0.64–1.82)
1.00 (0.68–1.46)
1.06 (0.64–1.75)
1.02 (0.71–1.45)
1.06 (0.67–1.69)
0.98 (0.69–1.39)
0.0%, 0.984, 1.000
0.0%, 0.806, 1.000
0.0%, 0.811, 1.000
0.0%, 0.691, 1.000
0.0%, 0.884, 1.000
0.0%, 0.736, 1.000
0.0, 0.778, 1.000
MMP-2
−735 C/T
Studies (cases/controls)
T versus C OR (95% CI) (%), ,
TT versus CC OR (95% CI) (%), ,
CT versus CC OR (95% CI) (%), ,
TT versus CT OR (95% CI) (%), ,
CT + TT versus CC OR (95% CI) (%), ,
TT versus CC + CT OR (95% CI) (%), ,
CT versus CC + TT OR (95% CI) (%), ,
Type of disease
CP
Caucasian
2 (236/234)
1.11 (0.79–1.55)
1.19 (0.43–3.37)
1.12 (0.74–1.68)
1.08 (0.37–3.13)
1.00 (0.67–1.49)
1.16 (0.41–3.24)
1.10 (0.74–1.65)
0.0, 0.695, 1.000
0.0, 0.511, 1.000
0.0, 0.940, 1.000
0.0, 0.541, 1.000
0.0, 0.699, 1.000
0.0, 0.522, 1.000
0.0, 0.989, 1.000
Smoking habit in CP
Caucasian
Nonsmoking
2 (133/198)
1.13 (0.74–1.72)
1.15 (0.32–4.09)
1.17 (0.70–1.94)
0.99 (0.27–3.66)
1.16 (0.71–1.88)
1.10 (0.31–3.89)
1.15 (0.69–1.90)
0.0, 0.337, 1.000
45.2, 0.177, 1.000
0.0, 0.784, 1.000
32.4, 0.224, 1.000
0.0, 0.533, 1.000
42.4, 0.188, 1.000
0.0, 0.917, 1.000
MMP-9
−1562 C/T
Studies (cases/controls)
T versus C OR (95% CI) (%), ,
TT versus CC OR (95% CI) (%), ,
CT versus CC OR (95% CI) (%), ,
TT versus CT OR (95% CI) (%), ,
CT + TT versus CC OR (95% CI) (%), ,
TT versus CC + CT OR (95% CI) (%), ,
CT versus CC + TT OR (95% CI) (%), ,
Type of disease
CP
Caucasian
2 (239/205)
0.56 (0.24–1.35)
0.36 (0.11–1.12)
0.63 (0.29–1.36)
0.51 (0.15–1.72)
0.57 (0.23–1.38)
0.39 (0.12–1.24)
0.72 (0.47–1.10)
78.2, 0.032, 1.000
35.9, 0.212, 0.553
64.0, 0.096, 1.000
0.0, 0.459, 1.000
73.9, 0.050, 1.000
20.4, 0.262, 0.777
57.1, 0.127, 0.924
Severe CP
Caucasian
Severe
2 (163/205)
0.63 (0.20–1.97)
0.44 (0.13–1.49)
0.71 (0.24–2.09)
0.53 (0.14–1.95)
0.65 (0.19–2.15)
0.46 (0.14–1.57)
0.75 (0.28–2.01)
86.1, 0.007, 1.000
54.4, 0.139, 1.000
79.3, 0.028, 1.000
0.0, 0.428, 1.000
84.2, 0.012, 1.000
41.0, 0.193, 1.000
76.0, 0.041, 1.000
MMP-1: matrix metalloproteinase-1; MMP-2: matrix metalloproteinase-2; MMP-9: matrix metalloproteinase-9; CP: chronic periodontitis; AgP: aggressive generalized periodontitis. : the value of heterogeneity; : the value corrected by Bonferroni correction; OR: odds ratio; CI: confidence interval. When is <0.1 and exceeds 50%, the random effects model is used. Conversely, the fixed effects model is used.
< 0.01 is considered statistically significant.
